Lung carcinoids with high proliferative activity: Further support for the identification of a new tumor category in the classification of lung neuroendocrine neoplasms. (October 2020)

• Record Type: Journal Article
• Authors: Rubino, M.; Scoazec, J.Y.; Pisa, E.; Faron, M.; Spaggiari, L.; Hadoux, J.; Spada, F.; Planchard, D.; Cella, C.A.; Leboulleux, S.; De Marinis, F.; Ducreux, M.; Lamartina, L.; Baudin, E.; Fazio, N.
• Is Part Of: Lung cancer. Volume 148(2020)
• Page Start: 149
• Page End: 158
• Publication Date: 2020-10
• Subjects: Carcinoids -- Ki67 -- Lung -- Neuroendocrine neoplasms; Lungs -- Cancer -- Periodicals; Lung Neoplasms -- Abstracts; Lung Neoplasms -- Periodicals; Poumons -- Cancer -- Périodiques; Lungs -- Cancer; Periodicals; Electronic journals; Electronic journals; 616.99424
• DOI: 10.1016/j.lungcan.2020.08.001
• Languages: English
• ISSNs: 0169-5002

Abstract

Highlights: NET G3 category exists also in the lung, although it is a very rare entity. Clinical behavior of lung NET G3 mimic those of AC, rather than lung NECs. Platinum/Etoposide resulted less active in our lung NET G3 compared with lung NECs. In this study Everolimus and PRRT results in a relatively long mPFS in lung NET G3. Abstract: Highly proliferative lung carcinoids (HPLC) have been recently reported but information about this subset remains scarce. Objectives: Clinical and pathological data of 630 patients with lung carcinoids (LC) referred to Gustave Roussy Institute (GR) and European Institute of Oncology (IEO) were retrospectively reviewed to select HPLC and analyze their frequency, behavior and compare their outcome to conventional LC with Ki-67 ≤ 20 % and mitotic count (MC)≤10/2 mm 2 . Materials and methods: Selection criteria were: diagnosis of LC confirmed by local pathologist, and available clinical and follow-up data. Patients with Ki-67 > 20 % and/or MC > 10/ 2 mm2 in primary or metastatic specimens were identified as HPLC. Results: 30/514 patients (6%) met the selection criteria of HPLC. Based on primary tumor evaluation, 22/25 (88 %) were classified as atypical carcinoids (AC). Median MC was 4.5/2 mm 2 (1–11) 6/2 mm 2 (3–15) in primary tumors and metastasis, respectively. Median Ki-67 was respectively 23 % (15–65) and 25 % (8–60). Recurrence rate was 66 % (12/18) in HPLC and 9 % (33/352) in conventional LC. Median RFS was 24 (10-NR) months in HPLC, 288 (141-NR) months in LC with Ki-67 index≤5 % and NR (148-NR) months in LC with Ki-67 6−20% (p < 001). Median OS was 203 (83-NR) months in LC with Ki-67 index≤5%, 101 (79-NR) months in LC with Ki-67 index 6−20 % and 53 (39-NR) months in HPLC (p = 002). Among 20 metastatic patients with HPLC, median PFS under platinum-based chemotherapy, everolimus, alkylating-based chemotherapy, FOLFOX and PRRT was 5.1 (95 % CI 0.7−9.4), 12.1(95 %CI 0.3−24), 6.8 (95 % CI 0−14.9), 10.2 (95 % CI 0.4−19.9) and 14.2 months (95 % CI 0-30) respectively. Best response was stable disease (SD) under platinum-based chemotherapy and partial response (PR) under alkylating-based chemotherapy and FOLFOX. Conclusion: This study confirms the existence and rarity of HPLC. Their characteristics and clinical behavior are more similar to LC rather than neuroendocrine carcinomas (NECs), suggesting that this entity could be managed accordingly.